Anandamide 是一种免疫调节剂，通过大麻素受体 CB1 和 CB2 起作用，还通过中枢神经系统中的其他靶点起作用，如 GPR18/GPR55。

Anandamide, an immune modulator, acts via not only cannabinoid receptors (CB1 and CB2) but also other targets (e.g., GPR18/GPR55) in the central nervous system.

Anandamide, acting via CB2 receptors, alleviates lipopolysaccharide (LPS)-induced neuroinflammation in rat primary microglial cultures. Endocannabinoids, especially Anandamide (AEA), can activate numerous other receptors like PPARS, TRPV1, and GPR18/GPR55 [1].

Anandamide is an endocannabinoid binding both CB1R and CB2R. To evaluate the impact of CBR activation on whole-body glucose homeostasis, glucose tolerance is assessed after a single intraperitoneal Anandamide injection (10 mg/kg). The increase in glycemia in response to glucose ingestion is considerably smaller in mice treated with Anandamide compared with control. It is associated with an improvement of glucose tolerance as illustrated by the AUC0-2h calculations[2].

94421-68-8

C22H37NO2

347.53

花生四烯酸乙醇胺;(5Z,8Z,11Z,14Z)-N-(2-Hydroxyethyl)icosa-5,8,11,14-tetraenamide

DMSO:250 mg/mL (719.36 mM)
Ethanol:10 mg/mL (28.77 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years